Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Por: González-Cao M, Arance A, Piulats JM, Marquez-Rodas I, Manzano JL, Berrocal A, Crespo G, Rodriguez D, Perez-Ruiz E, Berciano M, Soria A, Castano AG, Espinosa E, Montagut C, Alonso L, Puertolas T, Aguado C, Royo MA, Blanco R, Rodríguez JF, Muñoz E, Mut P, Barron F, Martin-Algarra S and Spanish Melanoma Group

---

Publicada: 1 jun 2017

---

---

Filiaciones:
González-Cao M:
 Translational Cancer Research Unit, Dr. Rosell Oncology Institute, Quiron Dexeus University Hospital, 08028, Barcelona, Spain.

Arance A:
 Hospital Clinic i Provincial, Barcelona, Spain

Piulats JM:
 Catalan Institute of Oncology, Barcelona, Spain

Marquez-Rodas I:
 Gregorio Marañón Institute of Health Research, Madrid, Spain

Manzano JL:
 Germans Trias I Pujol University Hospital, Barcelona, Spain

Berrocal A:
 General University Hospital, Valencia, Spain

Crespo G:
 Burgos University Hospital, Burgos, Spain

Rodriguez D:
 Insular University Hospital of Gran Canaria, Canary Islands, Spain

Perez-Ruiz E:
 Costa del Sol Hospital, Marbella, Malaga, Spain

Berciano M:
 Regional University Hospital of Malaga, Malaga, Spain

Soria A:
 Ramony Cajal Hospital, Madrid, Spain

Castano AG:
 Marqués de Valdecilla University Hospital, Santander, Spain

Espinosa E:
 La Paz University Hospital, Madrid, Spain

Montagut C:
 Del Mar University Hospital, Barcelona, Spain

Alonso L:
 Virgen de la Victoria Hospital, Malaga, Spain

Puertolas T:
 Miguel Servet University Hospital, Zaragoza, Spain

Aguado C:
 San Carlos Hospital, Madrid, Spain

:
 Dr. Peset Hospital, Valencia, Spain

Blanco R:
 Consorci Sanitari de Terrassa, Barcelona, Spain

Rodríguez JF:
 Clara Campal Hospital, Madrid, Spain

Muñoz E:
 Valld'Hebron University Hospital, Barcelona, Spain

Mut P:
 Son Llatzer University Hospital, Mallorca, Spain

Barron F:
 National Cancer Institute, Mexico City, Mexico

Martin-Algarra S:
 Navarra University Clinic, Pamplona, Spain